NCT07105098 - NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Biotech Hunter

Enrollment

284

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Schizophrenia

Interventions

DRUG

NBI-1117568

NBI-1117568 will be administered per schedule specified in the arm description.

DRUG

Placebo

Placebo will be administered per schedule specified in the arm description.

Trial Locations (5)

RECRUITING

Neurocrine Clinical Site, Atlanta

RECRUITING

Neurocrine Clinical Site, North Canton

RECRUITING

Neurocrine Clinical Site, Culver City

RECRUITING

Neurocrine Clinical Site, Riverside

RECRUITING

Neurocrine Clinical Site, Garden Grove